Hepion Pharmaceuticals director Gary S. Stetz II files initial beneficial ownership statementPUBT·Jul 10 at 06:50 PMHEPA+55.99%
Hepion Pharmaceuticals director Danina Fisher files initial beneficial ownership statementPUBT·Jul 8 at 03:30 PMHEPA+55.99%
Hepion Pharmaceuticals appoints Danina Fisher, Gary S. Stetz II to boardPUBT·Jul 2 at 03:32 PMHEPA+55.99%
Hepion Pharmaceuticals holds annual shareholder meeting, votes on director slatePUBT·Jun 17 at 03:16 PMHEPA+55.99%
Vincent LoPriore Discloses Investment at Hepion Pharmaceuticals with 21.46% StakeTradingView·May 1 at 04:36 PMHEPA+55.99%LABU+0.28%
Hepion Pharmaceuticals Raises $700,000 in Private Placement of 17.5M Shares at $0.04TradingView·Apr 22 at 03:53 PMHEPA+55.99%FBT+0.18%
Helus Pharma Expresses Support for Executive Order Advancing Psychedelic Research and Regulatory Pathways for Serious Mental Health Conditions | HELP Stock NewsStockTitan·Apr 19 at 11:15 PMHELP+3.07%
Hepion Pharmaceuticals 2025 10-K: $0 Revenue, $(0.88) EPS on $(8.28) M Net LossTradingView·Mar 12 at 05:15 AMBIB-0.55%XLV-0.19%
Hepion Pharmaceuticals acquires ctRNA biomarker assay to detect liver cancer early, with possible applications for other solid tumors.Unusual Whales·Mar 3 at 06:36 AMIBB-0.27%IXJ-0.35%
